Verrica Pharmaceuticals Inc. (VRCA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

15/25

Growth 4 Margin 4 Expansion 3 Platform 1 Financial 3

latest quarter score

Earnings Reports

15
Verica Pharmaceuticals (VRCA) Q2 2026: YCAMP Units Surge 28% as Global Expansion and Pipeline Advance
August 07, 2026
15
Verica (VRCA) Q1 2026: YCANTH Applicator Units Jump 51% as Prescriber Base Expands
June 17, 2026
15
Verica Pharmaceuticals (VRCA) Q2 2025: Ycanth Applicator Units Jump 33%, Non-Dilutive Capital Bolsters Pipeline
June 16, 2026
18
Verica Pharmaceuticals (VRCA) Q3 2025: YCAMP Dispensed Units Up 33% as Focused Commercial Model Drives Expansion
June 16, 2026
17
Verica Pharmaceuticals (VRCA) Q4 2025: YCANTH Revenue Doubles, Margin Expands to 85.7% as Pipeline Advances
June 15, 2026
12
Verrica Pharmaceuticals (VRCA) Q1 2025: YCANTH Dispensed Units Cross 10,000, Signaling Strengthened Commercial Traction
May 13, 2025
15
Verrica Pharmaceuticals (VRCA) Q4 2024: 12.3% Sequential Growth in YCANTH Units Signals Early Commercial Turnaround
March 11, 2025

Browse all companies